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Abstract 
 
Corporate research and development (R&D) activities have long been highly concentrated in a 
handful of world cities. This is due to the fact that these cities (e.g., Tokyo, New York, London, 
and Paris) are home to the largest and most powerful transnational corporations and are globally 
important sites for innovative start-up firms that operate in the fastest growing industries. 
However, in tandem with the rapid technological changes of our age, corporate R&D activities 
have shifted towards newly emerging and now globally significant R&D centres, like San Jose, 
San Francisco, and Boston in the United States, and Beijing, Seoul, and Shenzhen in East Asia. 
In this paper, I will conduct a bibliometric analysis to define which cities are centres of 
corporate R&D activities, how different industries influence their performance, and what spatial 
tendencies characterise the period from 1980 to 2014. The bibliometric analysis is based upon 
an assumption that implies there is a close connection between the number of scientific articles 
published by a given firm and the volume of its R&D activity.   
 Results show that firms headquartered in Tokyo, New York, London, and Paris 
published the largest combined number of scientific articles in the period from 1980 to 2014, 
but that the growth rate of the annual output of scientific articles was much greater in Boston, 
San Jose, Beijing, and Seoul, as well as some Taiwanese cities. Furthermore, it can also be seen 
that those cities that have the largest number of articles; i.e., that can be considered as the most 
significant sites of corporate R&D in which firms operate in fast-growing industries, are 
primarily in the pharmaceutical and information technology industries. For these reasons, some 
mid-sized cities that are home to globally significant pharmaceutical or information technology 
firms are also top corporate R&D hubs.   
 
Keywords: scientific article, corporate research and development, R&D-oriented firms, fast-
growing industries 
 
1. Introduction 
 
Since the beginning of the 1970s, but even in the past quarter century, the rate at which the 
global economy is restructuring has rapidly increased. This restructuring has been characterised 
by, for example, the emergence of the new international division of labour (NIDL) (Fröbel et 
al. 1980, Cohen 1981), as well as rapid technological changes (Dicken, 2007). Transnational 
corporations, as key orchestrators within the framework of economic globalization, have been 
relocating manufacturing activities away from core industrial countries towards developing 
countries for decades (Schoenberger, 1988; Dicken, 2007). As a result, some developing 
countries, especially China and India, have gradually become key actors in the world economy. 
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Recently in these developing countries, many giant low-tech manufacturing corporations and 
banks have been established, as well as a growing number of innovative small and medium-
sized enterprises (Cheng, 2014), all of which have the power to significantly affect the world 
economy (Sauvant, 2008). Furthermore, in the recent past, technological change has occurred 
at a rapid pace due in part to fast-growing industries like nanotechnology, biotechnology, and 
information technology Hullmann, Meyer 2003; Nicolini, Nozza 2008; Dernis et al. 2015). 
Naturally, core economies still dominate in these industries; however, some developing 
countries have become serious competitors. For example, China has become a global player in 
the telecommunication and renewable energy industries. The gap between the economic 
performance of developed and developing countries has gradually narrowed, thanks not only to 
the fast economic growth of developing countries, but also to the large volume of foreign direct 
investments that target their corresponding R&D sector (Reddy, 2005). Several firms from 
developing countries have emerged as globally significant R&D investors (Hernández et al., 
2015), and have themselves become major actors in global corporate R&D activities (Csomós, 
Tóth, 2016a).  
Clearly, the spatial distribution of corporate R&D activities is highly uneven, because 
of the fact that the majority of R&D-oriented firms, and even their research facilities, are 
concentrated in just a few cities in the world. According to Sassen’s (2001) global city concept, 
New York, London, Tokyo, and Paris are the most important sites for the production of 
innovation; i.e., they are expected to be the greatest centres of global corporate R&D activities. 
However, in tandem with the rapid technological changes of our age, corporate R&D activities 
have shifted towards newly emerging and globally significant R&D centres, like San Jose, San 
Francisco, and Boston in the United States (Rothwell et al., 2013), and Beijing, Seoul, and 
Shenzhen in East Asia. In recent years, these cities have become home to many R&D-oriented 
firms that did not even exist in the 1980s or 1990s.  
 In this paper, I will conduct a bibliometric analysis to define which cities are centres of 
corporate R&D activities, how different industries influence their performance, and what spatial 
tendencies characterise the period from 1980 to 2014. The structure of this paper is as follows: 
First, I will present the reasons firms have scientific articles; second, I will demonstrate the data 
and methodology by way of bibliometric analysis; and finally, I will draw the conclusion.   
 
2. Research background 
 
2.1. How can corporate R&D activities be measured? 
 
The volume of corporate R&D activities can be measured in different ways; for example, by 
counting the number of patents and/or the number of patent citations (Narin et al., 1987; Chang 
et al., 2012; Liu et al., 2006; Ribeiro et al., 2010; Ribeiro et al, 2014; Wang et al., 2011; Wong, 
Wang, 2015); by counting the amount in R&D expenditures (Granstrand, 1999; Kumar, 2001; 
Piergiovanni, Santarelli, 2013; Yoo, Moon, 2006); by defining the quantity and quality of 
research cooperation between firms and universities (Feng et al., 2015; Gao et al., 2011; Kneller 
et al., 2014; Ramos-Vielba et al., 2010); and by the number of scientific articles authored or co-
authored by researchers within the firms (Chang, 2014; Furukawa, Goto, 2006; Hicks et al., 
1994; Hicks, 1995; Hullmann, Meyer, 2003; Tijssen, 2004; Csomós, Tóth, 2016a). The latter 
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method is confirmed by Narin et al. (1987: 144), who addressed the product life cycle of 
corporations:  
“Corporate sales lead to corporate profits, which may be used in research and development to 
produce scientific innovations (scientific publications), which may lead to technological 
innovations (some of which will be patented), which is the catalyst for new products and more 
efficient processes, which will increase corporate profits.”  
Thus, the number of scientific articles authored/co-authored by corporate researchers or 
engineers can reflect upon the R&D capacity of firms.  
 
2.2. Why do firms have scientific publications? 
 
Not every firm publishes scientific papers; not even some that have many patents or a large 
budget for R&D expenditures. Although, it is generally believed that scientific publishing is 
out of business organizations’ interest, firms publish papers, and they do it extensively (Hicks, 
1995; Godin, 1996). Some firms contribute as many scientific articles to public literature as do 
medium-sized universities. For example, between 1980 and 2014, IBM published more 
scientific articles than did Carnegie Mellon University, which was ranked 61st on the 2015 
ARWU ranking. Firms’ motivations regarding publishing differs between countries and across 
industries, and is largely influenced by the firm’s individual intellectual property strategy. 
 Next, I will provide an overview on the main reasons that firms contribute scientific 
articles, or at minimum, why firms have scientific articles indexed by bibliographic databases 
(e.g., Web of Science, Scopus). 
 
2.2.1. Enabling defensive publications 
 
A firm that has a patentable innovation can choose from any or all of these three options. First, 
the firm can obtain a patent; second, it can maintain trade secrecy; and third, it can publish an 
enabling defensive publication1 (Johnson, 2014). Each option has benefits and risks that must 
be considered by the firm. The primary cost of a defensive publication is that it discloses the 
technical information of a product or process to the public, allowing competitors to capitalise 
on the innovation free of charge. Consequently, the innovating firm loses the right to exclude 
others from producing, selling, or using the patented innovation for the term of the patent, which 
is usually 20 (+5 extra) years from the filing date. The main benefit of an enabling publication 
is that it destroys patent rights. According to Barrett (2002: 191), “the successful defensive 
publication renders the competitor’s invention obvious or lacking in novelty.” 
Enabling defensive publications has been a component of comprehensive intellectual 
property (IP) strategies of firms, even the largest transnational corporations, for decades. IBM 
produced its Technical Disclosure Bulletin between 1958 and 1998 to publish defensive 
                                                          
1 There are three options to protect innovations and inventions (www.defensivepublications.org): 
1) Obtain a patent. A patent is the right, granted by a government (in exchange for full disclosure), to exclude 
others from making, using or selling products and services for a period of time (generally twenty years from the 
filing date). 
2) Maintain secrecy. Innovations or inventions that are safeguarded from disclosure to others by policies and 
procedures are trade secrets. They are generally protected as long as secrecy is maintained. 
3) Publish an enabling defensive publication. 
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disclosures of inventions that were not formally patented. By having done this, IBM lost the 
possibility of patenting a number of innovations; however, the cumulative benefits enjoyed by 
the firm were much higher by destroying competitors’ patent rights (Barrett, 2002). The 
Bulletin, as prior art, is referred to in a US patent document more than 48,000 times. Recently, 
defensive publication has become a widely used tool for small and medium-sized enterprises 
(SMEs) to protect intellectual property instead of patenting innovations. This choice of strategy 
has several reasons behind it; however, the two most important ones are that patent applications 
are too expensive for SMEs (primarily in the United States), and it takes an average of two 
years from the date of filing to process an application (The New York Times, 2002).     
The phenomenon of defensive publication significantly contributes to the increase in the 
number of firms’ scientific publications2. 
 
2.2.2. Enhancing the reputation of the firm 
 
Many firms encourage their researchers and engineers to disclose knowledge publicly in order 
to improve the external reputation of the firm (Hicks, 1995; Li et al., 2015). The improved 
reputation achieved via open knowledge disclosure can result in many benefits for a given firm 
(Muller, Pénin, 2006). First, reputable firms can more easily find investors or obtain grants and 
subsidies. Second, they can more easily find potential collaborators with whom they can work 
on joint R&D projects. Third, these firms are more readily accepted for involvement in broader 
academic and industrial networks, resulting in additional benefits for them. Fourth, these firms 
can attract and hire star researchers to work on the firms’ R&D projects. The improved 
reputation of the firm may counterweight the losses in profits (Allen, 1983), furthermore, 
reputational gains from being published in scientific publications give credibility to a firm in 
its research field (Li et al., 2015).  
 It can be concluded that scientific publication by firms can be considered on some level 
as quasi-scientific advertisements to target other innovative firms and researchers, informing 
them of the firm’s leadership in relevant R&D projects. 
 
2.2.3. Recruiting and retaining researchers 
 
According to Godin (1996), firms are not generally interested in publishing scientific papers 
because their main motivation is to develop patentable innovations, which increases corporate 
profits. Therefore, before patenting innovations, researchers are not permitted by their firm to 
publish their results (i.e., disclose the technical information behind innovations to the public). 
The reasoning is apparent: Patents are valuable in terms of money, while scientific publications 
are not (unless defensive publishing is a component of the firm’s IP strategy) (Levi-Mazloum, 
von Ungern-Sternberg, 1990; Pain, 2009). This restriction against publishing may discourage 
many researchers from working for firms for a higher salary but a lower scientific reputation, 
                                                          
2 Defensive publications do not necessarily correspond to scientific publications. The Ip.com Prior Art Database 
contains the largest number of enabling defensive publications in the world. Although these defensive publications 
may provide new knowledge by disclosing technical information about innovations, they are not considered 
scientific publications because they are not, among other things, peer-reviewed, not indexed in citation databases, 
etc.      
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as many are more likely to be committed to working in academia for a lower salary but a greater 
scientific reputation. This conflict may lead to an extreme situation: either firms not being able 
to hire researchers for their R&D projects, or researchers leaving the firm upon being restricted 
from publishing. In order to avoid this situation, a compromise must be made between the 
management and researchers, in which researchers ask permission before publishing their 
scientific results, with cooperation from the management in allowing researchers to publish 
(Furukawa & Goto, 2006). This compromise has key benefits for both parties. 
 
2.2.4. Collaboration with universities 
 
Collaboration between firms and universities on R&D projects has always had great 
significance. According to Kneller et al. (2014), “motivations for firms to engage with 
universities include accessing complementary research expertise for future business 
development, particularly for products that are in the design or early development stage, 
furthermore, small or new firms tend to rely on universities for their core technologies.” The 
results of this kind of collaboration can be patentable innovations (which are important to the 
firm), as well as joint scientific publications (which are important to academicians) (Ramos-
Vielba 2010). In many cases, corporate researchers and engineers contribute to the writing of a 
paper only by providing technical guidance, professional supervision, and necessary data; they 
do not participate directly in the creation of the paper. However, as quasi co-authors, their 
names and their affiliations appear in the paper, which then will be indexed by bibliographic 
databases. Thus, the firm, as the affiliate of corporate researchers, will enjoy credit in a scientific 
publication, even if it was not directly involved in writing the paper. 
 
3. Data collection 
 
In this paper, I conducted a bibliometric analysis of data in the Scopus database 
(www.scopus.com). Scopus is the largest abstract and citation database, containing almost 
22,000 titles (20,800 peer-reviewed journals, 367 trade publications, and more than 400 book 
series) from 5,000 publishers, in addition to 6.4 million conference papers. Scopus offers the 
most broad and integrated coverage available of scientific, technical, medical, and social 
sciences including arts and humanities literature. In this analysis, I focus on full articles 
exclusively, leaving out of consideration all other types of publications (for example, 
conference papers, book chapters, letters, and editorials), which do not necessarily go through 
a peer-review process. Articles, written by given firms’ researchers and engineers, have been 
assigned to cities as was indicated by Scopus.   
The 2015 EU Industrial R&D Investment Scoreboard ranks the world’s top 2,500 R&D-
investing firms, which together invested $681.9 billion in R&D, representing about 90 percent 
of the world’s total expenditure by businesses on R&D. Leading R&D investor firms are 
classified into 41 industry sectors, and are headquartered in 475 cities across 40 countries 
worldwide (Hernández et al., 2015). However, only 1,027 out of the 2,500 firms have scientific 
articles indexed in Scopus, and these firms are headquartered in 261 cities. Researchers and 
engineers at these firms contributed a total number of 958,725 scientific articles in the period 
from 1980 to 2014. Furthermore, it is needed to be mentioned that articles can be written by 
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multiple authors who affiliate to multiple organizations, i.e. a given article can be assigned to 
not only one, but multiple corporations. 
 
4. Results 
 
4.1. General results of corporate scientific publishing 
 
4.1.1. Correlation between industry sectors and number of scientific articles 
 
Previous studies underline the fact that most R&D-oriented firms are involved in high-tech 
industries (e.g., pharmaceuticals, information technology, chemicals, and electronics), and as 
such, they publish the largest number of scientific publications (Godin, 1996; Chang, 2014). 
Table 1 shows that the Pharmaceuticals & Biotechnology industry contributed nearly 29 percent 
of the total number of articles, even though the share of the number of firms that operate in this 
industry is under 13 percent. Thanks to Nippon Telegraph & Telephone (NTT), the number of 
articles per firm is actually the largest in the Fixed Line Telecommunications industry, in which 
NTT contributed 64 percent of the total number of articles. 
 
Table 1. Ranking industry sectors by the number of scientific articles published by firms 
in the period from 1980 to 2014 
Rank Industrial sector (ICB-3D) No. of firms 
No. of articles 
(1980-2014) 
No. of articles 
per firm 
Percentage 
within the 
dataset 
1 Pharmaceuticals & Biotechnology 317 276,215 871 28.81 
2 Technology Hardware & Equipment 317 103,874 328 10.83 
3 Electronic & Electrical Equipment 229 79,406 347 8.28 
4 General Industrials 96 75,002 781 7.82 
5 Software & Computer Services 275 69,606 253 7.26 
6 Chemicals 133 62,012 466 6.47 
7 Oil & Gas Producers 32 53,771 1680 5.61 
8 Automobiles & Parts 155 45,379 293 4.73 
9 Fixed Line Telecommunications 17 35,267 2075 3.68 
10 Aerospace & Defence 56 24,233 433 2.53 
11 Industrial Metals & Mining 40 18,710 468 1.95 
12 Industrial Engineering 199 17,795 89 1.86 
13 Food Producers 59 17,809 302 1.86 
14 Leisure Goods 39 16,247 417 1.69 
15 Health Care Equipment & Services 100 13,132 131 1.37 
16 Electricity 30 10,799 360 1.13 
17-41 Other industry sectors 412 39,468 - 4.12 
 TOTAL 2506 958,725 383 100.00 
 
Table 2 shows those industry sectors of cities in which more than 10,000 articles were created 
in the period from 1980 to 2014. Recognizing the fact that the largest number of articles belongs 
to pharmaceuticals, it is not surprising that the Pharmaceuticals & Biotechnology category is 
the most important industrial component of leading cities. For example, 23 pharmaceutical 
firms headquartered in New York published as many articles as did 275 information technology 
firms (classified into the Software & Computer Services category) in the period from 1980 to 
2014. Furthermore, some leading cities (Tokyo, New York, and Paris) had more than one 
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industry in which firms published a very large number of articles; i.e., they carried out extensive 
R&D activities.    
 
Table 2. Ranking industry sectors in cities by the number of scientific articles published 
by firms  
Rank City/Metro Country Industrial sector (ICB-3D) No. of firms 
No. of 
articles 
(1980-2014) 
Percentage 
within the 
sector 
1 New York United States Pharmaceuticals & Biotechnology 23 69,871 25.30 
2 London United Kingdom Pharmaceuticals & Biotechnology 8 42,646 15.44 
3 New York United States Software & Computer Services 13 39,742 57.10 
4 Basel Switzerland Pharmaceuticals & Biotechnology 4 39,062 14.14 
5 Tokyo Japan Electronic & Electrical Equipment 24 35,548 44.77 
6 Paris France Technology Hardware & Equipment 4 32,786 31.56 
7 New York United States General Industrials 4 26,172 34.90 
8 San Jose United States Technology Hardware & Equipment 63 22,502 21.66 
9 Tokyo Japan Fixed Line Telecommunications 1 22,467 63.71 
10 Beijing China Oil & Gas Producers 3 18,575 34.54 
11 Paris France Pharmaceuticals & Biotechnology 8 17,885 6.48 
12 Tokyo Japan Software & Computer Services 6 17,126 24.60 
13 Tokyo Japan General Industrials 10 16,670 22.23 
14 Tokyo Japan Pharmaceuticals & Biotechnology 15 16,654 6.03 
15 Amsterdam Netherlands General Industrials 1 14,385 19.18 
16 Cologne Germany Pharmaceuticals & Biotechnology 1 13,538 4.90 
17 Munich Germany Electronic & Electrical Equipment 2 13,252 16.69 
18 Tokyo Japan Automobiles & Parts 21 13,022 28.70 
19 Indianapolis United States Pharmaceuticals & Biotechnology 1 12,765 4.62 
20 Philadelphia United States Chemicals 3 11,972 19.31 
21 Tokyo Japan Chemicals 28 10,862 17.52 
22 Detroit United States Automobiles & Parts 10 10,678 23.53 
23 Nagoya Japan Automobiles & Parts 12 10,139 22.34 
24 Bridgeport United States General Industrials 1 10,031 13.37 
25-602 Cities’ other industry sectors 1410 420,375  
 TOTAL 1676 958,725  
 
4.1.2. Cities as centres of global corporate R&D 
 
The preceding industry-specific ranking suggests that Tokyo and New York are leading sites 
of corporate R&D. Table 3 illustrates that these cities were home to two-thirds of the total 
number of articles published by selected firms in the period from 1980 to 2014. Tokyo is the 
leading headquarter location of corporate R&D investors, as headquarters to nine percent of all 
firms in the data set. As home to 78 firms on the list, New York is also a significant headquarters 
city; moreover, New York-based IBM, Pfizer, Honeywell, and Merck are all Top 10 firms in 
terms of the number of scientific articles published. It is not surprising that Paris and London, 
two European global cities, are in leading positions, because both cities are strong 
pharmaceutical industry bases (London-based firms include GlaxoSmithKline and 
AstraZeneca; Paris-based firms include Sanofi and Servier), furthermore Paris is home to 
Alcatel-Lucent, which published the second-largest number of scientific articles in the 1980 to 
2014 time frame, after IBM.    
 
Table 3. Ranking cities by the total number of scientific articles published by 
headquartered firms 
8 
 
Rank City/Metro Country No. of firms 
No. of articles (1980-
2014) 
Percentage within 
the dataset 
1 Tokyo Japan 227 171,917 17.93 
2 New York United States 78 140,329 14.64 
3 Paris France 70 72,173 7.53 
4 London United Kingdom 84 60,751 6.34 
5 Basel Switzerland 8 41,098 4.29 
6 San Jose United States 110 29,088 3.03 
7 Osaka Japan 78 26,774 2.79 
8 Chicago United States 34 20,220 2.11 
9 Beijing China 63 19,607 2.05 
10 Amsterdam Netherlands 14 19,545 2.04 
11 Seoul South Korea 66 18,629 1.94 
12 Munich Germany 22 17,127 1.79 
13 Dallas United States 12 16,879 1.76 
14 Bridgeport United States 9 16,244 1.69 
15 Boston United States 84 14,549 1.52 
16 Cologne Germany 4 13,656 1.42 
17 Philadelphia United States 23 12,960 1.35 
18 Indianapolis United States 3 12,765 1.33 
19 Nagoya Japan 32 11,876 1.24 
20 Detroit United States 11 10,678 1.11 
21 Washington United States 24 10,407 1.09 
22 Oxnard United States 4 7919 0.83 
23 San Francisco United States 89 7292 0.76 
24 Houston United States 15 7069 0.74 
25 The Hague Netherlands 2 6981 0.73 
26 Copenhagen Denmark 16 6848 0.71 
27 Seattle United States 16 6591 0.69 
28 Zurich Switzerland 25 6426 0.67 
29 Mainz Germany 1 5843 0.61 
30 Helsinki Finland 20 5531 0.58 
31 Minneapolis United States 17 5256 0.55 
32 Cincinnati United States 3 5098 0.53 
33 Midland, Michigan United States 1 5082 0.53 
34 Ludwigshafen Germany 1 5056 0.53 
35-261 Other cities - 929 120,461 12.56 
 TOTAL 2195 958,725 100.00 
 
The four global cities, New York, London, Tokyo, and Paris, are followed by Basel 
(Switzerland) and San Jose (United States). Basel is a leading site in the international 
pharmaceutical industry: Basel-based Novartis and Roche both belong to Top 10 firms in terms 
of the number of published scientific articles. Table 3 shows that Basel is home to only eight 
significant corporate R&D investors, but San Jose is the headquarters of 110 relevant firms. In 
the period from 1980 to 1984, the listed Basel-based firms published 2.4 times as many articles 
as did the firms in San Jose. This ratio lessened to 1.2:1 in the period from 2009 to 2014, 
emphasizing that the gap between Basel and San Jose is closing.   
 It should be noted that in the period from 1980 to 2014, the vast majority of the total 
number of scientific articles (87.44 percent) were published by firms located in developed 
countries. Out of the 34 top-ranked cities (see Table 3), 17 cities are located in the United States, 
12 in Western Europe, three in Japan, and one in South Korea. The category of leading cities in 
developing countries is represented only by Beijing.       
 
4.2. The most intensive period of publishing 
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The United States is the dominant actor in corporate R&D activities. In the period from 1980 
to 2014, 38 percent of the total number of scientific articles came from US firms. Western 
Europe and Japan are both important locations of corporate R&D activities as well, publishing 
33 percent and 22 percent of the total number of articles, respectively. All the other countries 
play a minor role in global corporate R&D, contributing only seven percent of the total number 
of articles. It is important to now analyse the spatial dynamics of scientific publishing. 
 Figure 1 shows the most intensive period of publishing by city; i.e., a five-year-long 
period in which firms located in a given city published the largest number of scientific articles. 
Cities are classified into three groups, depending on whether their most intensive period of 
publishing fell into the time frame 1) between 1980 and1984, and 1999 and 2003; 2) between 
2000 and 2004, and 2009 and 2013; or 3) between 2010 and 2014. It can be seen that the three 
major areas: the United States, Western Europe, and Japan, are spatially divided regarding their 
most intensive period of publishing. Perhaps Japan is an exception, because its key cities’ most 
intensive period came to an end before 2013; moreover, in the cases of Tokyo and Osaka, the 
two most important cities in terms of the number of articles, this five-year-long period fell in 
the 1990s.  
 Many major cities on the West Coast and the East Coast of the United States have 
become international centres of corporate R&D activities, while cities in the Great Lakes region 
and the state of Texas have lost their leading positions. Information technology firms have 
contributed the largest number of scientific articles in Seattle and San Jose, while in the cases 
of Oxnard, San Diego, and San Francisco, pharmaceutical firms have published a great number 
of articles. On the East Coast of the United States, Boston-based biotechnology and 
pharmaceutical firms have contributed the largest number of articles; furthermore, some highly 
specialised firms located in small and medium-sized cities have also published a great number 
of articles (e.g., Corning, New York: Corning Inc.; Hartford, Connecticut: United 
Technologies).  
The Great Lakes region and the state of Texas are home to many transnational 
corporations that operate in traditional industries, like oil, chemicals, and automotive. Some of 
these firms had once been among the world’s largest firms (e.g. General Motors and 
ExxonMobil), but after the recession of the late 2000s, and in part due to the recent low oil 
prices, they have come into a crisis, or in some cases, have been recovering slowly. Because of 
their financial problems, these firms have cut their R&D expenditures and reduced the size of 
the R&D staff, which has naturally resulted in a decrease in the number of scientific articles.  
In the period from 1980 to 2014, the largest number of scientific articles in the United 
States was published by New York-based firms. New York is home to several global 
pharmaceutical firms, including Merck, Pfizer, Johnson & Johnson, and Bristol-Myers Squibb, 
whose most intensive year of publishing was 2011; however, since that time, there has been a 
significant decrease. The peak of scientific publishing within the information technology 
industry, which is the second most dominant industry sector in New York in terms of scientific 
output, was 1989 to 1993, but since that time, it has also witnessed a decrease in the number of 
articles published. 
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Fig. 1. Mapping spatial distribution of leading cities as centres of corporate R&D in light 
of the most intensive period of publishing 
 
In Europe, cities that are home to large pharmaceutical firms; for example, Dublin, 
Copenhagen, Basel, and Darmstadt, showed a marked increase in the number of scientific 
articles. The most surprising among these cities is Dublin, a relative newcomer to the 
pharmaceutical industry. Basel and Darmstadt have long been home to major pharmaceutical 
firms: the histories of Basel-based Roche and Novartis, and that of Darmstadt-based Merck, are 
inseparable from the histories of their headquarter cities. Copenhagen is the European centre of 
several medium-sized pharmaceutical firms and fast-growing biotechnology firms, which were 
all founded in Denmark. In contrast with these cities, Dublin has attracted pharmaceutical firms 
(and some more large research-oriented firms) from other countries, especially from the United 
States. US firms, including Allergan, Perrigo, Eaton, Seagate, and Accenture, relocated their 
headquarters, and in some cases, the entire firm, to Dublin, because the Irish capital offered low 
corporate taxes and well-developed business infrastructure (The New York Times, 2015). 
 However, as illustrated in Table 3, the most significant European sites for corporate 
R&D were Paris and London. Firms in these two cities published the largest number of 
scientific articles in the period from 1980 to 2014. For London-based firms, the most intensive 
period of publishing was 2007 to 2011, but by 2010 to 2014, a decrease of less than five percent 
occurred. In contrast, firms in Paris published the largest number of articles in the period from 
1996 to 2000, and since then the city showed a 46 percent decline by 2010 to 2014. In London, 
two global pharmaceutical firms, GlaxoSmithKline and AstraZeneca, published 59 percent of 
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the articles. The decline in London’s annual output was mainly attributed to GlaxoSmithKline, 
which decreased its publishing activity by nine percent by 2014. In Paris, there were two 
dominant firms as well: Alcatel-Lucent, a global telecommunications equipment firm, and 
Sanofi, one of the world’s largest pharmaceutical firms. These two firms published 64 percent 
of all articles of Paris. Alcatel-Lucent contributed about 33,000 articles in the period from 1980 
to 2014, about 45 percent of the total number of the Paris-based firms’ scientific articles. 
Alcatel-Lucent published 7,323 articles in its most intensive period of 1987 to 1991. Its less 
intensive period was 2010 to 2014, when the firm only contributed 1,095 articles, which 
translates to an 85 percent decrease in the number of articles over the course of 15 years. Since 
the beginning of the 2000s, Alcatel has desperately attempted to compete with its Asian rivals 
(such as ZTE and Huawei), and even the company’s 2006 acquisition of the American Lucent 
did not result in success (Financial Times, 2012). Between 2006 and 2015, the merged Alcatel-
Lucent suffered a cumulative loss of $13 billion; meanwhile, both its revenues and market 
values fell significantly. In 2006, Alcatel also acquired Lucent’s Bell Laboratories, one of the 
world’s largest research facilities and owner of a great number of patents and scientific 
publications. Alcatel-Lucent still had a globally outstanding R&D expenditure in 2013, but it 
was not as much as the independent firms’ combined expenditures had been in the 1990s (also 
reflected by the fact that the number of scientific articles has gradually decreased since the late 
1980s). Alcatel-Lucent could not avoid selling its shares in other firms (e.g., in Thales and 
Genesys), or even its own acquisition. In 2016, Finland-based Nokia, one of the world’s largest 
telecommunication network equipment firms, acquired Alcatel-Lucent and Bell Labs, and 
organised them into quasi-autonomous subsidiaries. In conclusion, up until 2014, Paris 
maintained a very good position in global corporate R&D, but after losing control of Alcatel-
Lucent, its leading role is fading away.    
 Since the mid-1990s, significant changes have occurred in the spatial structure of 
corporate R&D in East Asia. The publishing activity by major Japanese firms that ruled the 
1990s has been gradually decreasing. For example, Tokyo- and Osaka-based firms published 
the largest number of scientific articles in 1996 respectively, but their annual output decreased 
by 45 percent by the year 2014. Regarding corporate publishing activity, there is no dominant 
firm in Tokyo. The city’s 10 largest firms in terms of the number of articles contributed only 
61 percent to the total number of articles published by all Tokyo-based firms. Although the 
annual output of articles has been decreasing in almost every industry sector, the negative 
change far exceeds the average in the electronic industry, one of Japan’s most important 
industries (The Economist, 2009). Among the Tokyo-based firms that contributed the largest 
number of articles were several electronic firms, including Hitachi (ranked 2nd), NEC (5th), 
Toshiba (6th), and Sony (11th), whose collective average annual output decreased by 34 percent 
from 1996 to 2014. In Osaka, another electronics giant, Panasonic, contributed the largest 
number of articles over the course of the study. Its most intensive year of publishing was in the 
mid-1990s; however, its annual output had decreased by 50 percent by the year 2014. Further 
adding to the losses, the fourth-largest Osaka-based firm in terms of the number of articles 
published, Sharp, has since been acquired by the Taiwanese Foxconn. 
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Fig. 2. Annual output of scientific articles by leading firms in Top 10 cities (1980-2014)  
 
In East Asia, Seoul and Beijing have recently shown a great increase in the number of articles 
published. Today these cities have become major competitors to the Japanese cities, not only 
as command and control centres (see, for example, Csomós, Tóth, 2016b), but also as sites of 
corporate R&D. However, there is a notable difference between Seoul and Beijing, that in the 
case of Beijing, 95 percent of the articles come from oil firms (Sinopec, PetroChina, and 
CNOOC), while in Seoul, the most productive industry sector is electronics, having 42 percent 
of the articles. Andersson et al. (2014: 2969) claim that although Beijing has similar publication 
volumes as for example, London and Paris, it still occupies a peripheral position in the 
production of new scientific breakthroughs. Recently, by establishing technology parks, Beijing 
has made a strong effort to attract foreign high-technology firms and provide an innovative 
environment for domestic start-up firms (Zhou, 2005; Ramirez and Li, 2009; Zhang et al, 2011).  
Outside the above regions, there are some less significant cities that are sites of corporate 
R&D; for example, Rio de Janeiro, Mumbai, and Melbourne, but together, they contribute only 
as many scientific articles as does the medium-sized city of Minneapolis.   
 
5. Conclusion  
 
In this paper, I conducted a bibliometric analysis to determine which cities were considered to 
be the international sites of corporate R&D, and how the publication performance of leading 
firms headquartered in these cities has changed between 1980 and 2014. Results show that cities 
13 
 
can be organised into five large R&D zones worldwide: the West Coast of the United States, 
the Great Lakes Region, the East Coast of the United States, Western Europe, and East Asia. 
The West Coast of the United States: The heart of this region is the San Francisco Bay 
Area (including San Jose and the cities of the Silicon Valley), which is the international centre 
of the information technology industry. The dominant city within this region is San Jose, having 
the largest number of scientific articles. Furthermore, it can be observed that many San Jose-
based firms have started to publish only since the mid-1990s, and as such, San Jose is one of 
the most dynamically growing sites of corporate R&D worldwide. Seattle, Oxnard, San Diego, 
and Los Angeles are also significant sites of corporate R&D; however, their combined number 
of scientific articles is less than 50 percent of that of San Jose.  
 The Great Lakes Region: Chicago, Indianapolis, Detroit, Minneapolis, Cincinnati, and 
Midland are the most important sites of corporate R&D in this zone. It is a common 
characteristic of these cities that although large firms headquartered within them carry out 
significant R&D activities, and many of them operate in high-tech industries (e.g., chemicals, 
pharmaceuticals, and aerospace and defence), actually none of them belong to the fast-growing 
industries. Albeit the fact that cities in this zone are still important sites of corporate R&D, 
leading firms are publishing a decreasing number of articles year by year. 
The East Coast of the United States: New York has the largest number of scientific 
articles published by firms, due to its globally outstanding pharmaceutical and information 
technology industry. New York is followed by some mid-sized R&D hubs, such as Bridgeport, 
Philadelphia, and Washington, DC. In this zone, the closest competitor to New York is Boston, 
the fastest-growing site of corporate R&D in the United States, especially in the fields of 
biotechnology and information technology.  
Western Europe: On the basis of the number of scientific articles, Paris and London are 
the major sites of corporate R&D in Europe; however, with respect to the increase in the number 
of articles, cities in Southern Germany and Switzerland show the most rapid increase. Basel is 
a leading R&D hub of the international pharmaceutical industry. Furthermore, Copenhagen and 
Dublin also have a key role in the European corporate R&D. In the former, scientific articles 
primarily come from domestic biotechnology firms; in the latter, most of the articles are 
published by relocated American firms. 
East Asia: The most dramatic changes have occurred in this region. Tokyo is the largest 
corporate R&D hub in the world: Tokyo-based firms published the largest combined number 
of articles in the period from 1980 to 2014; moreover, the city has had the largest annual output 
in terms of the number of scientific articles published since the mid-1980s. However, the 
volume of this annual output has been gradually decreasing; that is, year by year, Tokyo-based 
firms (and firms headquartered in Osaka and Nagoya) have been publishing fewer and fewer 
articles. In this region, Seoul and Beijing has become the most dynamically growing R&D hub, 
also reflected by the fact that firms headquartered in Seoul and Beijing have been publishing a 
rapidly growing number of scientific articles. The difference between Seoul and Beijing is that 
in the former, most articles are coming from high-tech firms, while in the latter, oil firms are 
publishing almost exclusively. 
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